179 related articles for article (PubMed ID: 24088226)
21. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Gaston C; Kolesar J
Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
[TBL] [Abstract][Full Text] [Related]
22. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
Stingl JC; Parmar S; Huber-Wechselberger A; Kainz A; Renner W; Seeringer A; Brockmöller J; Langsenlehner U; Krippl P; Haschke-Becher E
Curr Med Res Opin; 2010 Nov; 26(11):2535-42. PubMed ID: 20849243
[TBL] [Abstract][Full Text] [Related]
23. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
[TBL] [Abstract][Full Text] [Related]
24. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.
Goetz MP; Suman VJ; Hoskin TL; Gnant M; Filipits M; Safgren SL; Kuffel M; Jakesz R; Rudas M; Greil R; Dietze O; Lang A; Offner F; Reynolds CA; Weinshilboum RM; Ames MM; Ingle JN
Clin Cancer Res; 2013 Jan; 19(2):500-7. PubMed ID: 23213055
[TBL] [Abstract][Full Text] [Related]
25. Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.
Fox P; Balleine RL; Lee C; Gao B; Balakrishnar B; Menzies AM; Yeap SH; Ali SS; Gebski V; Provan P; Coulter S; Liddle C; Hui R; Kefford R; Lynch J; Wong M; Wilcken N; Gurney H
Clin Cancer Res; 2016 Jul; 22(13):3164-71. PubMed ID: 26847054
[TBL] [Abstract][Full Text] [Related]
26. No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.
Markkula A; Hjertberg M; Rose C; Ingvar C; Jernström H
Acta Oncol; 2014 Feb; 53(2):195-200. PubMed ID: 24125101
[TBL] [Abstract][Full Text] [Related]
27. CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.
He W; Eriksson M; Eliasson E; Grassmann F; Bäcklund M; Gabrielson M; Hammarström M; Margolin S; Thorén L; Wengström Y; Borgquist S; Hall P; Czene K
Ann Oncol; 2021 Oct; 32(10):1286-1293. PubMed ID: 34284099
[TBL] [Abstract][Full Text] [Related]
28. CYP2D6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients.
Chin FW; Chan SC; Abdul Rahman S; Noor Akmal S; Rosli R
Breast J; 2016; 22(1):54-62. PubMed ID: 26510986
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.
Serrano D; Lazzeroni M; Zambon CF; Macis D; Maisonneuve P; Johansson H; Guerrieri-Gonzaga A; Plebani M; Basso D; Gjerde J; Mellgren G; Rotmensz N; Decensi A; Bonanni B
Pharmacogenomics J; 2011 Apr; 11(2):100-7. PubMed ID: 20309015
[TBL] [Abstract][Full Text] [Related]
30. The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.
Teh LK; Mohamed NI; Salleh MZ; Rohaizak M; Shahrun NS; Saladina JJ; Shia JK; Roslan H; Sood S; Rajoo TS; Muniandy SP; Henry G; Ngow HA; Hla U KT; Din J
AAPS J; 2012 Mar; 14(1):52-9. PubMed ID: 22183189
[TBL] [Abstract][Full Text] [Related]
31. Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy.
Thota K; Prasad K; Basaveswara Rao MV
Asian Pac J Cancer Prev; 2018 Feb; 19(2):343-350. PubMed ID: 29479969
[TBL] [Abstract][Full Text] [Related]
32. Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.
Brewer NT; Defrank JT; Chiu WK; Ibrahim JG; Walko CM; Rubin P; Olajide OA; Moore SG; Raab RE; Carrizosa DR; Corso SW; Schwartz G; Peppercorn JM; McLeod HL; Carey LA; Irvin WJ
Public Health Genomics; 2014; 17(1):43-7. PubMed ID: 24457521
[TBL] [Abstract][Full Text] [Related]
33. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
Province MA; Goetz MP; Brauch H; Flockhart DA; Hebert JM; Whaley R; Suman VJ; Schroth W; Winter S; Zembutsu H; Mushiroda T; Newman WG; Lee MT; Ambrosone CB; Beckmann MW; Choi JY; Dieudonné AS; Fasching PA; Ferraldeschi R; Gong L; Haschke-Becher E; Howell A; Jordan LB; Hamann U; Kiyotani K; Krippl P; Lambrechts D; Latif A; Langsenlehner U; Lorizio W; Neven P; Nguyen AT; Park BW; Purdie CA; Quinlan P; Renner W; Schmidt M; Schwab M; Shin JG; Stingl JC; Wegman P; Wingren S; Wu AH; Ziv E; Zirpoli G; Thompson AM; Jordan VC; Nakamura Y; Altman RB; Ames MM; Weinshilboum RM; Eichelbaum M; Ingle JN; Klein TE;
Clin Pharmacol Ther; 2014 Feb; 95(2):216-27. PubMed ID: 24060820
[TBL] [Abstract][Full Text] [Related]
34. A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
Johansson H; Gandini S; Serrano D; Gjerde J; Lattanzi M; Macis D; Guerrieri-Gonzaga A; Aristarco V; Mellgren G; Lien E; DeCensi A; Bonanni B
Breast Cancer Res Treat; 2016 Aug; 159(1):97-108. PubMed ID: 27484880
[TBL] [Abstract][Full Text] [Related]
35. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
[TBL] [Abstract][Full Text] [Related]
36. Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.
Zafra-Ceres M; de Haro T; Farez-Vidal E; Blancas I; Bandres F; de Dueñas EM; Ochoa-Aranda E; Gomez-Capilla JA; Gomez-Llorente C
Int J Med Sci; 2013; 10(7):932-7. PubMed ID: 23781139
[TBL] [Abstract][Full Text] [Related]
37. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer.
Li J; Humphreys K; Eriksson L; Edgren G; Czene K; Hall P
J Clin Oncol; 2013 Jun; 31(18):2249-56. PubMed ID: 23610119
[TBL] [Abstract][Full Text] [Related]
38. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
[TBL] [Abstract][Full Text] [Related]
39. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
[TBL] [Abstract][Full Text] [Related]
40. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
Hertz DL; Snavely AC; McLeod HL; Walko CM; Ibrahim JG; Anderson S; Weck KE; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Peppercorn JM; Evans JP; Jones DR; Desta Z; Flockhart DA; Carey LA; Irvin WJ
Br J Clin Pharmacol; 2015 Nov; 80(5):1122-30. PubMed ID: 25907378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
